The Silicon Review
We activate our clients and our teams as we work together to connect key healthcare providers and stakeholders to the therapies they need to treat their patients and to help improve their lives: Kelly Simpson-Angelini
Growth, major changes, and strong value-creation potential make healthcare an exciting industry. At the same time, uncertainty and complexity make it an unnerving one. Because of these factors, profit pool growth has varied widely over the last five years across the healthcare sector, ranging from negative growth to growth above 10 percent.
Looking ahead, growth will continue to be driven by innovation, and winners will be those who can deliver value-creating solutions, thrive under uncertainty and spot and effectively respond to opportunitiesas they arise.
In view of the above mentioned, we are delighted to present Simpson Healthcare Executives, LLC – a global leader in biopharmaceutical marketing and communications, dedicated to driving therapeutic innovations forward.
The company was established in 1998 and is headquartered in Old Lyme, Connecticut. It has many remote locations throughout the United States in the West, Mid-West, and Southern states.
Simpson Healthcare Executives has most recently been designated as “Best for Scientific Communications” by Corporate Vision Magazine and “Best Scientific Communications Agency-CT” by the 2017 Business Excellence Awards, hosted by Acquisition International Magazine. Earlier this year, the company was crowned “Best Pharmaceutical Marketing Support Specialists-CT” at the 2017 North American Excellence Awards, a prestigious national awards program held by Corporate America News that is committed to organizations that provide excellence in client service.
Interview Excerpt: Kelly Simpson-Angelini, CEO/CSO
Why was the company set up? And how did you expand your company and its offerings over the years?
Simpson Healthcare Executives challenges key stakeholders in the healthcare industry to think disruptively about the future of healthcare and we collaborate to create the most positive experiences for patients, beyond the immediate future and into the next couple of decades. Healthcare is a broad industry ecosystem, and innovation is central to transforming and evolving our industry so that we can fulfil the overarching goal of healthcare: helping people live better. For the past 20 years, Simpson Healthcare has had the opportunity to work with great pharmaceutical clients and has focused our efforts on supporting them in the development of new therapies. The scientific expertise and disruptive thinking methods and behaviors among the elite members of our organization span across a broad array of many major disease categories, including respiratory, oncology, cardiovascular, rare diseases, gastrointestinal, adult vaccines, and severe asthma, to name a few. This expertise has led our medical and strategy teams to be catalysts of industry innovation as we bring to bear the larger context of healthcare for our clients, while always keeping the patient at the center of our focus. Our purpose is to support our clients to share the scientific story of the diseases they touch and therapies they discover for all in need.
As a leading global innovator, Simpson Healthcare is working on some of the biggest blockbuster brands in many leading therapeutic spaces and activating insights in whole disease categories that are ripe for disruption. Our transformative vision for the healthcare experience accelerates scientific advancements in our industry as we work to develop the ‘better brand’ for our clients. We expand medical conversations and communicate scientific information to key physicians and healthcare stakeholders as we push beyond current boundaries of science and expectation. We drive forward physician education surrounding the innovations that can significantly impact how a disease is treated, and improve quality of life for patients into the future.
“Earning trust and respect of consumers all around the world is through consistent focus on delivering high quality in all of our actions.” How do you interpret this statement?
We believe that the real value of healthcare resides in our ability to create value for patients and that our agency’s commitment to delivering the most positive patient experience for our clients in all of their interactions with the healthcare system is the best way to transform healthcare into the future. We understand that the role of the disease or product is one piece of a larger story that includes the patient and their caregivers, the healthcare providers, the health system that must be navigated, and the client’s strategic intent. Along with our clients, we keep the patient firmly in our sights as a core element of the story. Our offerings include traditional medical and scientific communications, but the diversity and experience within our organization allows us to bear the larger context of healthcare that facilitates high-level, strategic consulting as an important part of what our company delivers for every project we work on with our clients.
We pull through the story of why our clients’ therapeutic brands matter for patients and how they will improve their lives. We dig deeper into the science of the therapies that our clients are developing and what it means for patients who could benefit the most from their therapy. At the start of a new project, our internal team will align with our client on strategic vision, project management details, and the long-term value that will be added to the healthcare industry throughout the entire therapeutic brand lifecycle. After working with our client to clearly define the problem or opportunity, we will then outline our objectives and timelines and move forward in a collaborative path.
Do you have any new products ready to be/getting ready to be launched?
To expand upon our commitment to the healthcare experience and scientific innovation for our clients, we have used our passion for healthcare and disruptive innovation to build and customize specialized service offerings that provide long-term value to their business and the healthcare field. Through the collaborations of the talented members of our team, we have developed and successfully implemented a new line of ‘Futuring’ work with our major ‘big pharma’ clients. In order to understand why this type of work accelerates disruptive innovation, we have to dig deeper into what ‘Futuring’ means. During Futuring, we envision the potential best and worst futures without any reference to present day. Once the Futures have been imagined, the drivers to reach those futures are identified, which helps identify opportunities to shape a ‘Desirable Future’ or avoid impact from an Undesirable Future’. The reason this work is important is that the purpose of Futuring is to look at global datasets, policies, and influential variables, and to disrupt key markets in healthcare with a longer 10-20-year vision for the future. These inventories are a starting point for change based on the identified opportunities from Futuring. Our work has been launched with our top clients who are disruptively transforming healthcare in the industry.
We are proud to unite and support our clients, to shape the future of healthcare so that the best therapeutic treatments may be available to provide a brighter health outlook for those in need.
CEO – The Brain Behind The Operation: A Brief Background
Kelly Simpson-Angelini: Kelly Simpson-Angelini began her career as a Research Scientist at Pfizer, before discovering her passion for providing education to physicians that help patients to live better through advancing scientific communications and catalyzing brand behavior for biopharmaceutical clients. Providing effective and efficient education to physicians on therapies can really improve quality of life for patients; empowering better disease management, and in the best-case scenario, help to put devastating diseases into remission. It is important to find out what patients really want and then to ensure that this is delivered. This is the type of agency that Kelly leads, and what she is doing really works. She challenges key stakeholders in the biopharmaceutical and medical industry to think differently and often disruptively about how to better deliver healthcare and why it matters for patients.
Over the years, Kelly’s scientific agency has had the privilege of working on game-changing, billion-dollar therapeutic brands for heritage clients such as Pfizer, Merck, Shire, Amgen, Genzyme, Genentech.
In 2016, she was named a Women of Innovation Honoree by the Connecticut Technology Council for her entrepreneurial vision and leadership. She has since been honored in New York City by Medical Marketing and Media (MM&M) as a 2017 Healthcare Transformers-Top 10 Innovation Catalyst; and by Business Worldwide Magazine as 2017 Healthcare Industry CEO of the Year-USA and 2017 Most Innovative CEO of the Year-USA at the 2017 Business Worldwide CEO Awards. Ms Simpson-Angelini was honored most recently this fall at the 2017 Stevie Awards for Women in Business, where she won Female Entrepreneur of the Year-Business Services: 11-2,500 Employees, Company of the Year: More than 10 Employees, and Most Innovative Company of the Year: More than 10 Employees.
Kelly currently serves as Chair of the Board of Directors at Can Do Multiple Sclerosis (MS), a non-profit organization that was founded by the Olympic skier, Jimmie Huega in 1984 with a purpose of helping people with multiple sclerosis live better.